Skip to content
2000
Volume 25, Issue 2
  • ISSN: 1389-4501
  • E-ISSN: 1873-5592

Abstract

Glaucoma is the most common cause of irreversible blindness worldwide. It is characterized by progressive optic nerve degeneration and loss of visual field. Pathological increased intraocular pressure is its main modifiable risk factor. Rho kinase inhibitors are developed as a new class of glaucoma medication that increases outflow facility from the conventional aqueous humor outflow pathway. Additionally, they also have neuroprotective and anti-scarring effects that can might increase the success rate of glaucoma filtration surgery. This review aims to summarize the current concept of Rho kinase inhibitors in the treatment of glaucoma from beach to bedside.

Loading

Article metrics loading...

/content/journals/cdt/10.2174/0113894501286195231220094646
2024-02-01
2025-05-31
Loading full text...

Full text loading...

/content/journals/cdt/10.2174/0113894501286195231220094646
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test